FRENALER CORT application

Comments Off on FRENALER CORT application

Forms and presentation

Freshener Cort tablets: Film-coated tablets: Box of 10.
Frencher Court Syrup: Syrup: Bottle 60 ml.

Composition

Frencher Cort tablets: Each tablet contains: Desloratadine 5 mg

Frencher Cort tablets: Each tablet contains: Desloratadine 5 mg, Betamethasone 0.6 mg. Excipients: pregelatinized starch; colloidal silicon dioxide; microcrystalline cellulose; crospovidone, siliconized talc; hydroxypropyl methylcellulose 3 cp; hydroxypropyl methylcellulose 6 cp, titanium dioxide, polyethylene glycol 400, polysorbate 80; Allura aluminum lake red.
Corticoster syrup: Each 100 ml contains Desloratadine 100 mg; Betamethasone 0.5 mg. Excipients: sorbitol 70% solution; sodium benzoate; sodium citrate; anhydrous citric acid; sodium edetate; banana flavoring; sugar; propylene glycol; purified water.

Properties

Pharmacological measures: Frenaler Cort combines the anti-inflammatory and anti-allergic effects of betamethasone with the non-drug antihistamine action of desloratadine.
Desloratadine is a long-acting tricyclic histamine antagonist product, with selective peripheral H1-receptor histamine antagonist activity. It inhibits the release of histamine from human mast cells. Symptoms are effectively controlled within 24 hours after one daily dose.
Glucocorticoids, such as betamethasone, cause profound and varied metabolic effects, and they alter the body’s immune response to various stimuli. Betamethasone exhibits stromg-glucocorticoid and weak mineralocorticoid effects.

Pharmacokinetics

Desloratadine is well absorbed after oral administration. It can be detected in plasma 30 minutes after ingestion, and peak plasma levels are reached approximately 3 hours after ingestion. There is no effect of food intake on absorption. Desloratadine and 3-hydroxydesloratadine bound to plasma proteins by 85% and 87% (±2), respectively. Protein binding was not altered in patients with impaired renal function. Desloratadine is metabolized to 3-hydroxydesloratadine, the active metabolite, which is subsequently glucuronidated. There is a subpopulation that is poor at metabolizing desloratadine, especially among blacks. The average elimination half-life of desloratadine is 27 hours. Elimination occurs as metabolites evenly distributed in the urine and feces. Desloratadine does not easily cross the blood-brain barrier. Desloratadine has shown age-related differences in pharmacokinetics in elderly patients, but they do not justify dose adjustment in the elderly. Increased AUC has been observed in patients with renal or hepatic impairment. Therefore, dose adjustment is recommended for these patients.
Betamethasone is well absorbed after oral administration. Betamethasone can be detected in plasma as early as 20 minutes after administration. Peak plasma concentrations are reached 2 hours after oral administration and gradually decrease over the following 24 hours. There is no relationship between plasma corticosteroid levels (total or unbound) and the therapeutic effect; the pharmacodynamic effect lasts longer than the measured plasma levels. The average half-life for betamethasone is ≥300 minutes, and the average biological half-life is approximately 36-54 hours. Natural glucocorticoids as well as glucocorticoids of synthetic origin, including Betamethasone, are metabolized in the liver.

Contraindications

Freniger is contraindicated in patients with known hypersensitivity to any of its ingredients or to other corticosteroids. Systemic fungal infections, active tuberculosis.

Indications

Cort Frenalera is indicated for the treatment of severe allergic conditions requiring combined administration of antihistamine and systemic corticosteroid: Atopic dermatitis, angioedema, urticaria, seasonal and prolonged allergic rhinitis, allergic reactions to food and medications, allergic contact dermatitis and allergic processes occurring to the eye such as allergic conjunctivitis.

Precautions

Dosage adjustment may be required depending on remission or exacerbation of the condition being treated, depending on the patient’s individual response to treatment and the patient’s exposure to emotional or physical stress, such as severe infection, surgery, or trauma. Patients may require up to 1 year of follow-up after discontinuing long-term treatment or treatment in which large doses of corticosteroids were administered.
Corticosteroids may mask some signs of infection, and new infections may occur during their use. Resistance and inability to localize infection may be reduced with corticosteroid use.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts (especially in children), glaucoma with possible damage to the optic nerves, and may increase the establishment of secondary eye infections due to fungi or viruses
Medium to high doses of corticosteroids can cause increased blood pressure, salt and water retention, and increased potassium excretion. These effects are less likely with synthetic derivatives unless they are used in high doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
Patients should not be vaccinated against smallpox during corticosteroid therapy. Other immunization procedures should also not be performed in patients who are on corticosteroids, especially at high doses, because of the possible risk of neurological complications and possible inhibition of antibody formation. Despite the above procedure, vaccination can be undertaken in a patient on corticosteroids as a replacement therapy, such as in patients with Addison’s disease.
Patients who are on corticosteroid immunosuppressant doses should be warned to avoid exposure to chickenpox or measles. Patients should also be warned that if they are exposed to corticosteroids, they should seek medical attention immediately. This is especially important in the case of children.
The minimum dose of corticosteroids should be used to monitor the condition of the patient being treated. When it is possible to reduce the dosage, the reduction should be gradual.
Rapid discontinuation of corticosteroid treatment may lead to secondary adrenocortical insufficiency, which can be avoided by gradual dose reduction. This type of relative insufficiency may persist for months after therapy is discontinued. Therefore, corticosteroid therapy should be restored in any stressful situation occurring during this period. If the patient is already being treated with corticosteroids, it may be necessary to increase their dose. Because mineralocorticoid secretion may be impaired, a saline and/or mineralocorticoid should be administered simultaneously. Corticosteroid has an increased effect on patients with hypothyroidism and patients with cirrhosis.
Corticosteroids should be used with caution in patients with ocular herpes simplex because of possible corneal damage.
Physical distress may occur with the use of corticosteroids. Existing emotional instability or psychotic tendencies may be exacerbated by corticosteroids.
Caution should be exercised when using corticosteroids in the following situations: nonspecific ulcerative colitis if there is a possibility of impending perforation, abscess, or other pyogenic infection; diverticulitis; recent bowel anastomoses; active or latent peptic ulcer disease; renal failure; hypertension; osteoporosis; and myasthenia gravis. Because corticosteroid-related complications depend on the dosage and duration of treatment, each patient needs a risk assessment of the substance.
The growth and development of infants and children on long-term corticosteroid therapy should be closely monitored, as growth rates may be altered and endogenous corticosteroid production inhibited. In some patients, corticosteroids may alter sperm motility and sperm counts.
Pediatric use: Cort Frenaler should not be administered to children under 2 years of age. Corticosteroids may alter growth rate: Growth of children on long-term treatment with corticosteroids should be closely monitored.

Side effects

At the recommended doses, Frenaler Cort has no clinically significant sedative effects. More commonly described adverse reactions in patients taking desloratadine include: pharyngitis, headache, dry mouth, drowsiness, fatigue, flu-like symptoms, myalgia, nausea, dizziness, dry throat, and dyspepsia. Less commonly reported adverse events include tachycardia, hypersensitivity reactions (rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), and elevated liver enzymes and bilirubin. Adverse reactions reported for betamethasone were similar to those reported for other corticosteroids and were related to dosage and duration of treatment. Usually these adverse reactions can be reversed or minimized with dose reduction, which is generally preferable to discontinuation of treatment.
Fluid and electrolyte disorders: sodium retention, potassium loss, hypokalemic alkalosis, fluid retention.
Cardiovascular: congestive heart failure in susceptible patients, hypertension.
Musculoskeletal: muscle weakness, steroid myopathy, loss of muscle mass, increased severity of myasthenia gravis, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humerus heads, pathological fracture of long bones, tendon rupture.
Gastrointestinal: gastric ulcer, digestive tract hemorrhage, pancreatitis, abdominal distension, peptic esophagitis.
Dermatological: impaired wound healing, skin atrophy, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, suppressed skin test reactions, allergic dermatitis, urticaria, angioedema.
Neurological: seizures, increased intracranial pressure with papilledema (pseudotumor cerebri), usually after stopping treatment, dizziness, headache.
Endocrine: menstrual irregularities, development of cushingoid condition, inhibition of intrauterine fetal growth or growth in pediatric patients, secondary adrenocortical and pituitary unresponsiveness (especially during stressful situations such as trauma, surgery or illness), reduced carbohydrate tolerance, manifestations of latent diabetes, increased insulin requirements or order hypoglycemic drugs for diabetes.
Ophthalmologic: posterior subcapsular cataract, increased intraocular pressure, glaucoma, exophthalmos.
Metabolic: negative nitrogen balance due to protein catabolism.
Psychiatric: euphoria, mood swings, depression, mental disorders, personality changes, increased excitability, insomnia.
Other: anaphylactoid or hypersensitivity reactions and hypotensive or shock-like reactions.

Dosage and Administration

Frencher Court Tablets: Adults and children 12 years of age and older: 1 tablet once daily.
Freshener’s Cord Syrup:
Adults and children 12 years and older: 5 ml once daily.
Children 6 to 11 years of age: 2.5 ml once a day.
Children 2-5 years of age: 1.25 ml once a day (1/4 teaspoon).
The dosage may be adjusted according to the needs of each patient. Treatment should be continued until an appropriate therapeutic response is observed. Adult patients with renal or hepatic impairment are advised to start treatment at half the recommended starting dose until a degree of therapeutic response is established.
Once an adequate therapeutic response has been achieved (suppression of allergic symptoms), treatment should be discontinued gradually, considering – if necessary – prescribing an antihistamine drug as the only medication.
Treatment should also be phased out if spontaneous remission is observed during the chronic condition.
If treatment must be discontinued after long-term use, the dose should be gradually reduced.
Patients who are exposed to unusual stressful situations unrelated to the treated condition may need to increase Frenaler’s Cort.

Overdose

Desloratadine: due to poor existing experience, overdose information is limited to drowsiness and a 9 bpm increase in mean heart rate. The QTc interval calculated by both the Bazett and Friedericia methods showed no significant changes, as with placebo. No clinically significant adverse events were reported.
Betamethasone: Acute overdose of corticosteroids, including betamethasone, is not expected to result in potentially fatal situations. It is also highly unlikely that a few days of overuse of corticosteroids should lead to harmful effects in the absence of predisposing factors (diabetes mellitus, glaucoma or active peptic ulcer disease) and without concomitant use of certain substances such as digitalis, coumarin-type anticoagulants or potassium-dependent diuretics.
Treatment: after proper evaluation of the patient, consider standard measures to remove any unabsorbed drug (vomiting, adsorption with activated charcoal, gastric lavage, or administration of saline laxatives). Desloratadine and 3-hydroxydesloratadine are not removed by hemodialysis. Medical monitoring is recommended, with special emphasis on the possible effects of corticosteroids on metabolism, the internal environment, and the digestive system. Symptomatic and supportive treatment is recommended. And if you need to go to the hospital, you can find clothes here

Desloratadine: due to poor existing experience, overdose information is limited to drowsiness and a 9 bpm increase in mean heart rate. The QTc interval calculated by both the Bazett and Friedericia methods showed no significant changes, as with placebo. No clinically significant adverse events were reported.
Betamethasone: Acute overdose of corticosteroids, including betamethasone, is not expected to result in potentially fatal situations. It is also highly unlikely that a few days of overuse of corticosteroids should lead to harmful effects in the absence of predisposing factors (diabetes mellitus, glaucoma or active peptic ulcer disease) and without concomitant use of certain substances such as digitalis, coumarin-type anticoagulants or potassium-dependent diuretics.
Treatment: after proper evaluation of the patient, consider standard measures to remove any unabsorbed drug (vomiting, adsorption with activated charcoal, gastric lavage, or administration of saline laxatives). Desloratadine and 3-hydroxydesloratadine are not removed by hemodialysis. Medical monitoring is recommended, with special emphasis on the possible effects of corticosteroids on metabolism, the internal environment, and the digestive system. Symptomatic and supportive treatment is recommended. And if you need to go to the hospital, you can find clothes here https://kaufspot.de